Summary of the British Transplantation Society UK Guidelines for Hepatitis e and Solid Organ Transplantation

Stuart McPherson*, Ahmed M. Elsharkawy, Michael Ankcorn, Samreen Ijaz, James Powell, Ian Rowe, Richard Tedder, Peter A. Andrews

*Corresponding author for this work

    Research output: Contribution to journalReview articlepeer-review

    46 Citations (Scopus)


    The incidence and prevalence of hepatitis E virus (HEV) infection has increased in many developed countries over the last decade, predominantly due to infection with genotype 3 (G3) HEV. Infection with HEV G3 is important in transplant recipients because it can persist in immunosuppressed individuals, leading, if untreated, to the development of chronic hepatitis and significant liver fibrosis. The British Transplantation Society (BTS) has developed Guidelines for "Hepatitis E and Solid Organ Transplantation" to inform clinical teams and patients about hepatitis E, to help increase the recognition of persistent hepatitis E infection, and to provide clear guidance on its management. This guideline was published on the BTS website in June 2017 and aims to review the evidence relating to the diagnosis and management of persistent hepatitis E in solid organ transplant recipients and the methods of prevention of HEV infection. In line with previous guidelines published by the BTS, the guideline has used the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) system to rate the strength of evidence and recommendations. This article includes a summary overview of hepatitis E and transplantation with key references, and the statements of recommendation contained within the guideline. It is recommended that the full guideline document is consulted for complete details of the relevant references and evidence base. This may be accessed at

    Original languageEnglish
    Pages (from-to)15-20
    Number of pages6
    Issue number1
    Publication statusPublished - 1 Jan 2018

    Bibliographical note

    Funding Information:
    S.M.P. is a speaker, consultancy or travel support from AbbVie, BMS, Gilead, MSD, Novartis and Roche. A.E. is a speaker, consultancy, research grant or travel support from Abbvie, Astellas, BMS, Chiesi, Gilead and MSD. I.R. is a speaker or travel support from AbbVie, Bayer, and Norgine. All the other authors declare no conflicts of interest.


    Dive into the research topics of 'Summary of the British Transplantation Society UK Guidelines for Hepatitis e and Solid Organ Transplantation'. Together they form a unique fingerprint.

    Cite this